CLONIDINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C9H9Cl2N3
Molecular Weight	230.0941
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

c1cc(c(c(c1)Cl)NC2=NCCN2)Cl

InChI

InChIKey=GJSURZIOUXUGAL-UHFFFAOYSA-N

InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)

HIDE SMILES / InChI

Molecular Formula	C9H9Cl2N3
Molecular Weight	230.0941
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018891s028lbl.pdf
Curator's Comment:: description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017407s037lbl.pdf | https://clinicaltrials.gov/ct2/show/NCT02177461 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022331lbl.pdf | https://clinicaltrials.gov/ct2/show/NCT00556959

Clonidine is a centrally acting α2 adrenergic agonist and imidazoline receptor agonist used to treat high blood pressure, attention deficit hyperactivity disorder, anxiety disorders, tic disorders, withdrawal (from either alcohol, opioids, or smoking), migraine, menopausal flushing, diarrhea, and certain pain conditions. Clonidine treats high blood pressure by stimulating α2 receptors in the brain, which decreases peripheral vascular resistance, lowering blood pressure. It has specificity towards the presynaptic α2 receptors in the vasomotor center in the brainstem. This binding decreases presynaptic calcium levels, thus inhibiting the release of norepinephrine (NE). It has also been proposed that the antihypertensive effect of clonidine is due to agonism on the I1 receptor (imidazoline receptor), which mediates the sympatho-inhibitory actions of imidazolines to lower blood pressure. Clonidines mechanism of action in the treatment of ADHD is to increase noradrenergic tone in the prefrontal cortex (PFC) directly by binding to postsynaptic α2A adrenergic receptors and indirectly by increasing norepinephrine input from the locus coeruleus. Clonidine indicated in the treatment of hypertension. Clonidine hydrochloride tablets may be employed alone or concomitantly with other antihypertensive agents. The US Food and Drug Administration (FDA) has approved clonidine for the treatment of attention deficit hyperactivity disorder (ADHD), under the trade name of Kapvay alone or with stimulants in 2010, for pediatric patients aged 6–17 years.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Alpha-2a adrenergic receptor 28 Target ID: CHEMBL1867 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27265687	Partial Agonist 102	30.2 nM [EC50]
Adrenergic receptor alpha-2 53 Target ID: CHEMBL2095158 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25521963	Partial Agonist 102	3.8 nM [Ki]
Alpha-2b adrenergic receptor 15 Target ID: CHEMBL1942 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22750139	Partial Agonist 102	31.6 nM [Ki]
Alpha-2c adrenergic receptor 20 Target ID: CHEMBL1916 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22750139	Partial Agonist 102	9.3 nM [Ki]
Adrenergic receptor alpha-1 71 Target ID: CHEMBL2094251 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8784451	Partial Agonist 102	290.0 nM [EC50]

Conditions

Condition	Modality	Highest Phase	Product
Hypertension 235 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017407s037lbl.pdf	Primary	Approved 4033	CATAPRES-TTS-1 Approved Use INDICATIONS & USAGE Clonidine hydrochloride tablets, USP are indicated in the treatment of hypertension. Clonidine hydrochloride tablets, USP may be employed alone or concomitantly with other antihypertensive agents. Launch Date 4.66214388E11
Attention deficit hyperactivity disorder 34 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022331s013lbl.pdf	Primary	Approved 4033	KAPVAY Approved Use INDICATIONS AND USAGE. KAPVAY® is a centrally acting alpha2-adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications Launch Date 1.25418235E12
Opioid withdrawal 2 Sources: https://clinicaltrials.gov/ct2/show/NCT03174067	Primary	Phase IV 30	CATAPRES-TTS-1 Approved Use INDICATIONS & USAGE Clonidine hydrochloride tablets, USP are indicated in the treatment of hypertension. Clonidine hydrochloride tablets, USP may be employed alone or concomitantly with other antihypertensive agents. Launch Date 4.66214388E11

C_max

Value	Dose	Co-administered	Analyte	Population
443 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022331s021lbl.pdf	0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered:		CLONIDINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
7313 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022331s021lbl.pdf	0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered:		CLONIDINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
12.57 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022331s021lbl.pdf	0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered:		CLONIDINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

Doses

Dose	Population	Adverse events
0.25 mg 2 times / day multiple, oral Studied dose Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Co-administed with:: Methylphenidate(54 mg/day) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.139	unhealthy, 13 years n = 1 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: 13 years Sex: M Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.139	Other AEs: Suicide attempt... Other AEs: Suicide attempt Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.139
2 mg 3 times / day multiple, oral Highest studied dose Dose: 2 mg, 3 times / day Route: oral Route: multiple Dose: 2 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5454324/	unhealthy, adult n = 1 Health Status: unhealthy Condition: hypertension Age Group: adult Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/5454324/	Sources: https://pubmed.ncbi.nlm.nih.gov/5454324/
0.2 mg 2 times / day multiple, oral Recommended Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Co-administed with:: Amphetamine Methylphenidate(54 mg/day) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108	unhealthy, median age 10 years n = 102 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: median age 10 years Sex: M+F Population Size: 102 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108	Disc. AE: Bradyphrenia... AEs leading to discontinuation/dose reduction: Bradyphrenia (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108
0.1 mg 2 times / day multiple, oral Recommended Dose: 0.1 mg, 2 times / day Route: oral Route: multiple Dose: 0.1 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108	unhealthy, median age 9 years n = 76 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: median age 9 years Sex: M+F Population Size: 76 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108	Disc. AE: Somnolence, Fatigue... AEs leading to discontinuation/dose reduction: Somnolence (3.9%) Fatigue (2.6%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108
0.2 mg 2 times / day multiple, oral Recommended Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108	unhealthy, median age 9 years n = 78 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: median age 9 years Sex: M+F Population Size: 78 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108	Disc. AE: Somnolence, Fatigue... AEs leading to discontinuation/dose reduction: Somnolence (6.4%) Fatigue (5.1%) Constipation (1.3%) Vomiting (1.3%) Electrocardiogram QT prolonged (1.3%) Rash (1.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108
0.1 mg 2 times / day steady, oral Dose: 0.1 mg, 2 times / day Route: oral Route: steady Dose: 0.1 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00884832	unhealthy n = 22 Health Status: unhealthy Condition: Fecal Incontinence Population Size: 22 Sources: https://clinicaltrials.gov/ct2/show/NCT00884832	Other AEs: Dry mouth, Drowsiness... Other AEs: Dry mouth (below serious, 16 patients) Drowsiness (below serious, 5 patients) Lightheadedness (below serious, 6 patients) Fatigue (below serious, 8 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00884832

AEs

AE	Significance	Dose	Population
Suicide attempt		0.25 mg 2 times / day multiple, oral Studied dose Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Co-administed with:: Methylphenidate(54 mg/day) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.139	unhealthy, 13 years n = 1 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: 13 years Sex: M Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.139
Bradyphrenia	1% Disc. AE	0.2 mg 2 times / day multiple, oral Recommended Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Co-administed with:: Amphetamine Methylphenidate(54 mg/day) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108	unhealthy, median age 10 years n = 102 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: median age 10 years Sex: M+F Population Size: 102 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108
Fatigue	2.6% Disc. AE	0.1 mg 2 times / day multiple, oral Recommended Dose: 0.1 mg, 2 times / day Route: oral Route: multiple Dose: 0.1 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108	unhealthy, median age 9 years n = 76 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: median age 9 years Sex: M+F Population Size: 76 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108
Somnolence	3.9% Disc. AE	0.1 mg 2 times / day multiple, oral Recommended Dose: 0.1 mg, 2 times / day Route: oral Route: multiple Dose: 0.1 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108	unhealthy, median age 9 years n = 76 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: median age 9 years Sex: M+F Population Size: 76 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108
Constipation	1.3% Disc. AE	0.2 mg 2 times / day multiple, oral Recommended Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108	unhealthy, median age 9 years n = 78 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: median age 9 years Sex: M+F Population Size: 78 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108
Electrocardiogram QT prolonged	1.3% Disc. AE	0.2 mg 2 times / day multiple, oral Recommended Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108	unhealthy, median age 9 years n = 78 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: median age 9 years Sex: M+F Population Size: 78 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108
Rash	1.3% Disc. AE	0.2 mg 2 times / day multiple, oral Recommended Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108	unhealthy, median age 9 years n = 78 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: median age 9 years Sex: M+F Population Size: 78 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108
Vomiting	1.3% Disc. AE	0.2 mg 2 times / day multiple, oral Recommended Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108	unhealthy, median age 9 years n = 78 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: median age 9 years Sex: M+F Population Size: 78 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108
Fatigue	5.1% Disc. AE	0.2 mg 2 times / day multiple, oral Recommended Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108	unhealthy, median age 9 years n = 78 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: median age 9 years Sex: M+F Population Size: 78 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108
Somnolence	6.4% Disc. AE	0.2 mg 2 times / day multiple, oral Recommended Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108	unhealthy, median age 9 years n = 78 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: median age 9 years Sex: M+F Population Size: 78 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf Page: nda/2010/022331Orig1s001.pdf - p.108
Dry mouth	below serious, 16 patients	0.1 mg 2 times / day steady, oral Dose: 0.1 mg, 2 times / day Route: oral Route: steady Dose: 0.1 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00884832	unhealthy n = 22 Health Status: unhealthy Condition: Fecal Incontinence Population Size: 22 Sources: https://clinicaltrials.gov/ct2/show/NCT00884832
Drowsiness	below serious, 5 patients	0.1 mg 2 times / day steady, oral Dose: 0.1 mg, 2 times / day Route: oral Route: steady Dose: 0.1 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00884832	unhealthy n = 22 Health Status: unhealthy Condition: Fecal Incontinence Population Size: 22 Sources: https://clinicaltrials.gov/ct2/show/NCT00884832
Lightheadedness	below serious, 6 patients	0.1 mg 2 times / day steady, oral Dose: 0.1 mg, 2 times / day Route: oral Route: steady Dose: 0.1 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00884832	unhealthy n = 22 Health Status: unhealthy Condition: Fecal Incontinence Population Size: 22 Sources: https://clinicaltrials.gov/ct2/show/NCT00884832
Fatigue	below serious, 8 patients	0.1 mg 2 times / day steady, oral Dose: 0.1 mg, 2 times / day Route: oral Route: steady Dose: 0.1 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00884832	unhealthy n = 22 Health Status: unhealthy Condition: Fecal Incontinence Population Size: 22 Sources: https://clinicaltrials.gov/ct2/show/NCT00884832

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 882	substrate 530	substrate 610	inhibitor 775

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 666 OCT1 254 L-type Ca2+ channels 14 K+ channels 23	CYP1A2 526 CYP1A1 179 CYP3A5 203 CYP2A6 266 CYP2B6 338 CYP2C8 354 CYP2C18 79 CYP2C19 500 CYP2E1 332 CYP2J2 34 CYP1B1 41

Drug as perpetrator

Target	Modality	Activity
P-gp 754	inhibitor 1612 Sources: https://www.sciencedirect.com/science/article/abs/pii/0006291X9091939P Page: 265.0	likely
L-type Ca2+ channels 15	inhibitor 1612 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0006899300025920 Page: abstract	no
K+ channels 23	inhibitor 1612 Sources: https://journals.lww.com/anesthesia-analgesia/Fulltext/2011/12000/Molecular_Mechanisms_of_the_Inhibitory_Effects_of.14.aspx Page: abstract	yes [IC50 1.21 uM]
OCT1 266	inhibitor 1612 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3129651/ Page: 3.0	yes

Drug as victim

Target	Modality	Activity
CYP1B1 41	substrate 1689 Sources: https://dmd.aspetjournals.org/content/38/9/1393.short Page: 1.0	no
CYP2A6 266	substrate 1689 Sources: https://dmd.aspetjournals.org/content/38/9/1393.short Page: 1.0	no
CYP2B6 338	substrate 1689 Sources: https://dmd.aspetjournals.org/content/38/9/1393.short Page: 1.0	no
CYP2C18 79	substrate 1689 Sources: https://dmd.aspetjournals.org/content/38/9/1393.short Page: 1.0	no
CYP2C19 500	substrate 1689 Sources: https://dmd.aspetjournals.org/content/38/9/1393.short Page: 1.0	no
CYP2C8 354	substrate 1689 Sources: https://dmd.aspetjournals.org/content/38/9/1393.short Page: 1.0	no
CYP2C9 530	substrate 1689 Sources: https://dmd.aspetjournals.org/content/38/9/1393.short Page: 1.0	no
CYP2E1 332	substrate 1689 Sources: https://dmd.aspetjournals.org/content/38/9/1393.short Page: 1.0	no
CYP2J2 34	substrate 1689 Sources: https://dmd.aspetjournals.org/content/38/9/1393.short Page: 1.0	no
CYP1A1 179	substrate 1689 Sources: https://dmd.aspetjournals.org/content/38/9/1393.short Page: abstract	yes
CYP1A2 526	substrate 1689 Sources: https://dmd.aspetjournals.org/content/38/9/1393.short Page: abstract	yes
CYP2D6 610	substrate 1689 Sources: https://dmd.aspetjournals.org/content/38/9/1393.short Page: abstract	yes
CYP3A4 882	substrate 1689 Sources: https://dmd.aspetjournals.org/content/38/9/1393.short Page: abstract	yes
CYP3A5 203	substrate 1689 Sources: https://dmd.aspetjournals.org/content/38/9/1393.short Page: abstract	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 796	inhibitor 786 Sources: https://www.sciencedirect.com/science/article/abs/pii/S1056871907002808 Page: 102.0

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY554135	https://www.001chemical.com/chem/4205-90-7
AK Scientific, Inc. (AKSCI)	M199	http://www.aksci.com/item_detail.php?cat=M199
Achemo Scientific Limited	AC-35091	http://www.achemo.com/product_view.asp?ID=132847
Alfa Chemistry	AP4205907-B	https://reagents.alfa-chemistry.com/product/clonidine-cas-4205-90-7-11302.html
Alfa Chemistry	AP4205907-A	https://reagents.alfa-chemistry.com/product/clonidine-solution-cas-4205-90-7-11301.html
Alfa Chemistry	4205-90-7	https://www.alfa-chemistry.com/clonidine-200-mg-cas-4205-90-7-item-291955.htm
Aurora Fine Chemicals LLC	A12.862.925	http://online.aurorafinechemicals.com/info?ID=A12.862.925
Aurum Pharmatech LLC	H1640	http://www.Aurumpharmatech.com/Product/ProductDetails/H1640
AvaChem Scientific	1506B	http://www.avachem.com/productSearch.asp?1506B
BLD Pharm	BD121967	http://www.bldpharm.com/products/4205-90-7.html
BLD Pharm	BD425824	http://www.bldpharm.com/products/54707-71-0.html
BioChemPartner	BCP07223	http://www.biochempartner.com/4205-90-7-BCP07223
Chem Scene	CS-0012297	http://www.chemscene.com/4205-90-7.html
ChemMol	49411858	http://www.chemmol.com/chemmol/49411858.html
ChemMol	99094595	http://www.chemmol.com/chemmol/99094595.html
ChemShuttle	181502	http://www.chemshuttle.com/catalogsearch/result/?q=4205-90-7&cat=
Chemspace	CSSB00011218712	https://chem-space.com/CSSB00011218712
Clearsynth	CS-T-13180	https://www.clearsynth.com/en/CST13180.html
Finetech	FT-0741246	http://www.finetechnology-ind.com/prod/detail/pub/4205-90-7.html
Hairui	HR135273	http://www.hairuichem.com/en/product/4205-90-7.html
Lab Network	LN00326971	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00326971
MedChem Express	HY-12721	https://www.medchemexpress.com/clonidine.html
MolPort	MolPort-001-779-668	https://www.molport.com/shop/molecule-link/MolPort-001-779-668
MolPort	MolPort-005-932-374	https://www.molport.com/shop/molecule-link/MolPort-005-932-374
Molcore	MC554135	https://www.molcore.com/product/4205-90-7
Parchem	28580	http://www.parchem.com/chemical-supplier-distributor/Clonidine-Hydrochloride-018580.aspx
Sigma-Aldrich	C-033_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/c033?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S524033	http://www.smolecule.com/products/s524033
Smolecule	S772548	https://www.smolecule.com/products/s772548
THE BioTek	bt-263892	https://www.thebiotek.com/product/inhibitors/bt-263892
THE BioTek	bt-291913	https://www.thebiotek.com/product/others/bt-291913
eNovation Chemicals	D673838	https://www.enovationchem.com/ProductDetails.asp?ProductID=D673838
mcule	MCULE-5017779690	https://mcule.com/MCULE-5017779690/

PubMed

Title	Date	PubMed
Letter: Dementia associated with clonidine therapy.	1975 Mar 15	1125640
Drug treatment options for irritable bowel syndrome: managing for success.	2001	11302287
Alpha2 adrenergic agonists for the management of opioid withdrawal.	2001	11279747
[Potentiation of local anesthesia in endonasal surgery].	2001	11247245
P75-expressing elements are necessary for anti-allodynic effects of spinal clonidine and neostigmine.	2001	11226704
Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure.	2001 Apr	11300430
Oops--wrong dose of epidural clonidine in children!	2001 Apr	11300396
Alpha2A-adrenoceptor mediated tachypnea in awake goats.	2001 Apr	11282385
Brain alpha(2)-adrenoceptors in monoamine-depleted rats: increased receptor density, G coupling proteins, receptor turnover and receptor mRNA.	2001 Apr	11264240
Sodium-induced rise in blood pressure is suppressed by androgen receptor blockade.	2001 Apr	11247793
Blockade by agmatine of catecholamine release from chromaffin cells is unrelated to imidazoline receptors.	2001 Apr 6	11301064
Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy.	2001 Feb	11301086
The impact of glycaemic control on autoregulation of glomerular filtration rate in patients with non-insulin dependent diabetes.	2001 Feb	11300610
Some behavioural effects of antidepressant drugs are time-dependent.	2001 Feb	11294483
Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial.	2001 Feb	11286609
Interactions of ligands at angiotensin II-receptors and imidazoline receptors.	2001 Feb	11286399
Comparison of the effects of clonidine and hydroxyzine on haemodynamic and catecholamine reactions to microlaryngoscopy.	2001 Feb	11270028
The use of baclofen in cluster headache.	2001 Feb	11252142
Differential effects of clonidine, dopamine, dobutamine, and dopexamine on basal and acid-stimulated mucosal blood flow in the rat stomach.	2001 Feb	11246314
Nitric oxide and central antihypertensive drugs: one more difference between catecholamines and imidazolines.	2001 Feb	11230279
Mortality after coronary artery occlusion in different models of cardiac hypertrophy in rats.	2001 Feb	11230273
Inhibition of the I(h) current in isolated peripheral nerve: a novel mode of peripheral antinociception?	2001 Feb	11180209
Partial agonist clonidine mediates alpha(2)-AR subtypes specific regulation of cAMP accumulation in adenylyl cyclase II transfected DDT1-MF2 cells.	2001 Feb	11160870
Effectiveness of apraclonidine 1% in preventing intraocular pressure rise following macular hole surgery.	2001 Feb	11159479
Noradrenergic dysfunction in the prefrontal cortex in depression: an [15O] H2O PET study of the neuromodulatory effects of clonidine.	2001 Feb 15	11239902
[Cardiovascular stress protection following anesthesia induction. Comparison of clonidine and esmolol].	2001 Jan	11220254
Do infant rats cry?	2001 Jan	11212634
Antagonistic effects of selective alpha1-adrenoceptor antagonists MDL73005EF and tamsulosin and partial agonists clonidine and tizanidine in rat thoracic aorta and rabbit iliac artery.	2001 Jan	11206183
Treatment of chronic hypertension with intravenous enalaprilat and transdermal clonidine.	2001 Jan	11198612
Chronic treatment with desipramine facilitates its effect on extracellular noradrenaline in the rat hippocampus: studies on the role of presynaptic alpha2-adrenoceptors.	2001 Jan	11191838
Apical uptake of organic cations by human intestinal Caco-2 cells: putative involvement of ASF transporters.	2001 Jan	11191835
Effect of chronic morphine treatment on alpha(2)-adrenoceptor mediated autoinhibition of transmitter release from sympathetic varicosities of the mouse vas deferens.	2001 Jan	11159688
Chronic treatment with reboxetine by osmotic pumps facilitates its effect on extracellular noradrenaline and may desensitize alpha(2)-adrenoceptors in the prefrontal cortex.	2001 Jan	11156576
[Low sensitivity of IGF-I, IGFBP-3 and urinary GH in the diagnosis of growth hormone insufficiency in slowly-growing short-statured boys. Grupo Español de Estudio de la Talla Baja].	2001 Jan 13	11181253
Effects of antisense to the (alpha)2A-adrenoceptors administered into the region of the locus ceruleus on behaviors in plus-maze and sexual behavior tests in sham-operated and castrated male rats.	2001 Jan 15	11160451
Galanin/alpha2-adrenoceptor interactions in telencephalic and diencephalic regions of the rat.	2001 Jan 22	11201077
Frequency dependent alpha(2)-adrenoceptor mediated modulation of excitatory junction potentials in guinea-pig mesenteric artery.	2001 Jan 5	11137866
Clonidine in preterm-infant caudal anesthesia may be responsible for postoperative apnea.	2001 Jan-Feb	11172519
Premedication modifies the quality of sedation with propofol during regional anesthesia.	2001 Mar	11305831
Clonidine-induced antinociception and locomotor hypoactivity are reduced by dexamethasone in mice.	2001 Mar	11291750
Noradrenergic modulation of calcium currents and synaptic transmission in the olfactory bulb of Xenopus laevis tadpoles.	2001 Mar	11285006
Ultrasonic vocalizations of preweanling rats: involvement of both alpha(2)-adrenoceptor and kappa-opioid receptor systems.	2001 Mar	11274995
Effects of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) on alpha2-adrenoceptors which regulate the synthesis and release of noradrenaline in the rat brain.	2001 Mar	11245411
The antinociceptive effect of intrathecal administration of epibatidine with clonidine or neostigmine in the formalin test in rats.	2001 Mar	11240085
The analgesic interaction between intrathecal clonidine and glutamate receptor antagonists on thermal and formalin-induced pain in rats.	2001 Mar	11226109
Neural circuits regulating pulsatile luteinizing hormone release in the female guinea-pig: opioid, adrenergic and serotonergic interactions.	2001 Mar	11207938
Prevention of ischemic ventricular tachycardia of Purkinje origin: role for alpha(2)-adrenoceptors in Purkinje?	2001 Mar	11179062
Gelatin microspheres crosslinked with D,L-glyceraldehyde as a potential drug delivery system: preparation, characterisation, in vitro and in vivo studies.	2001 Mar 14	11250103
Alpha-adrenergic agonists inhibit the dipsogenic effect of angiotensin II by their stimulation of atrial natriuretic peptide release.	2001 Mar 23	11259763
Linkage study of the alpha2A adrenergic receptor in attention-deficit hyperactivity disorder families.	2001 Mar 8	11304829

Patents

Sample Use Guides

In Vivo Use Guide

Oral Initial Dose 0.1 mg tablet twice daily (morning and bedtime). Elderly patients may benefit from a lower initial dose Maintenance Dose Further increments of 0.1 mg per day may be made at weekly intervals if necessary until the desired response is achieved. Taking the larger portion of the oral daily dose at bedtime may minimize transient adjustment effects of dry mouth and drowsiness. The therapeutic doses most commonly employed have ranged from 0.2 mg to 0.6 mg per day given in divided doses. Studies have indicated that 2.4 mg is the maximum effective daily dose, but doses as high as this have rarely been employed. Transdermal: once every 7 days to a hairless area of intact skin on the upper outer arm or chest.

Route of Administration: Other

In Vitro Use Guide

Neural membranes (P2 fractions) were prepared from the prefrontal cortex of human brains obtained at autopsy. Specific Clonidine binding was measured in 0.55 mL aliquots (50 mM Tris HCl, pH 7.5) of the neural membranes, which were incubated with [3H]RX821002 (1 nM) for 30 min at 25 °C in the absence or presence of the Clonidine (10^-12 M to 10^-3 M, 10 concentrations). Specific binding was determined and plotted as a function of the compound concentration. Incubations were terminated by diluting the samples with 5 mL of ice-cold Tris incubation buffer (4 °C). Membrane-bound [3H]RX821002 was separated by vacuum filtration through Whatman GF/C glass fiber filters. Then the filters were rinsed twice with 5 mL of incubation buffer and transferred to minivials containing 3 mL of OptiPhase “HiSafe” II cocktail and counted for radioactivity by liquid scintillation spectrometry.

Substance Class	Chemical Created by `admin` on `Fri Jun 25 20:54:07 UTC 2021` Edited by `admin` on `Fri Jun 25 20:54:07 UTC 2021`
Record UNII	MN3L5RMN02
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CLONIDINE

Official Name

English

CLONIDINE [VANDF]

Common Name

English

CLONIDINE [WHO-DD]

Common Name

English

ST-155-BS

Code

English

CLONIDINE [HSDB]

Common Name

English

CLONIDINE [USP-RS]

Common Name

English

CLONIDINE EXTENDED RELEASE

Common Name

English

CLONIDINE [MI]

Common Name

English

CLONIDINE [USAN]

Common Name

English

CLONIDINE [JAN]

Common Name

English

CATARPRES-TTS

Brand Name

English

CLONIDINE [MART.]

Common Name

English

CLONIDINE [ORANGE BOOK]

Common Name

English

2-((2,6-DICHLOROPHENYL)IMINO)IMIDAZOLIDINE

Systematic Name

English

CLONIDINE [INN]

Common Name

English

CLONIDINE [USP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

WHO-ATC

C02LC51